Aβ1-42 promotes microglial activation and apoptosis in the progression of AD by binding to TLR4

Rui-Xia Dou1, Ya-Min Zhang2, Xiao-Juan Hu2

  • 1The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, 730000, Gansu, China; Department of Neurology, Gansu Provincial People's Hospital, Lanzhou, 730000, Gansu, China.

Redox Biology
|November 17, 2024
PubMed

Insights

Alzheimer's disease (AD) pathogenesis involves microglial activation. Targeting Toll-like receptor 4 (TLR4) reduces inflammation and apoptosis, offering a potential therapeutic strategy for AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia with complex mechanisms and no effective treatments.
  • Microglia play a crucial role in neuroinflammation associated with AD pathogenesis.
  • Beta-amyloid protein 1-42 (Aβ1-42) is implicated in AD, triggering microglial activation and inflammatory responses.

Purpose of the Study:

  • To investigate the role of Toll-like receptor 4 (TLR4) in Aβ1-42-induced microglial activation and apoptosis.
  • To explore the potential of modulating TLR4 as a therapeutic target for Alzheimer's disease.

Main Methods:

  • An Alzheimer's disease cell model was established by incubating microglia with Aβ1-42.
  • Toll-like receptor 4 (TLR4) expression was manipulated (knockdown and overexpression) in activated microglia.
  • Changes in cell morphology, inflammatory factor expression, apoptosis rates, and Tau protein levels were analyzed.

Main Results:

  • Aβ1-42 induced microglial activation, increased inflammatory factors, promoted apoptosis, and elevated Tau protein expression.
  • Knockdown of TLR4 significantly reduced inflammatory factors, inhibited apoptosis, and decreased Tau protein levels.
  • Overexpression of TLR4 exacerbated these effects, indicating TLR4 mediates Aβ1-42-induced pathology.

Conclusions:

  • Aβ1-42 activates microglia and promotes apoptosis, at least partly, through binding to TLR4.
  • Reducing TLR4 expression mitigates neuroinflammation and apoptosis in AD models.
  • TLR4 represents a promising therapeutic target for Alzheimer's disease prevention and treatment.